Ph 2, Double-Masked, Randomized, Parallel, Sham Surgery/Placebo Control, Multi-Center Study to Evaluate Systemic IMT Regimens as Graft Rejection Prophylaxis Following Transplantation of hESC Derived RPE Cells in Patients With AMD

Trial Profile

Ph 2, Double-Masked, Randomized, Parallel, Sham Surgery/Placebo Control, Multi-Center Study to Evaluate Systemic IMT Regimens as Graft Rejection Prophylaxis Following Transplantation of hESC Derived RPE Cells in Patients With AMD

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 29 Jul 2017

At a glance

  • Drugs MA09 retinal pigment epithelial cell replacement therapy-Advanced Cell Technology (Primary)
  • Indications Dry age-related macular degeneration
  • Focus Adverse reactions
  • Acronyms PORTRAY
  • Sponsors Astellas Institute for Regenerative Medicine
  • Most Recent Events

    • 25 Jul 2017 Planned End Date changed from 1 May 2019 to 5 May 2019.
    • 25 Jul 2017 Planned primary completion date changed from 1 May 2017 to 5 May 2017.
    • 25 Jul 2017 Status changed from discontinued to withdrawn prior to enrolment.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top